StockNews.AI
BTSG
StockNews.AI
166 days

BrightSpring Health Services, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Increases Full Year 2025 Guidance

1. BTSG reported Q4 revenue of $3.053 billion, a 28.6% increase. 2. BTSG achieved net income of $15.4 million, compared to a loss last year. 3. Full year revenue reached $11.266 billion, increasing by 27.6% from 2023. 4. Guidance for 2025 revenue increased to $11.6-$12.1 billion. 5. Divestiture of Community Living business expected to enhance capital flexibility.

34m saved
Insight
Article

FAQ

Why Very Bullish?

BTSG's significant revenue growth and profitability turnaround position it well for future growth, similar to past successes like the surge after the introduction of their pharmacy solutions division, which enhanced their revenue stream substantially.

How important is it?

The significant financial improvements and future guidance suggest a compelling investment thesis, with strong indicators of sustained growth, significantly impacting investor sentiment and market attractiveness for BTSG.

Why Long Term?

The diversifying strategies and increased guidance indicate strong potential for sustained growth. Past divestitures have also led to strategic advantages and boosted performance over the long run.

Related Companies

SEVAMEDHCA
LOUISVILLE, Ky., March 06, 2025 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ: BTSG), a leading provider of home and community-based health services for complex populations, today announced financial results for the fourth quarter and full year ended December 31, 2024, and increased revenue and Adjusted EBITDA¹ guidance. Financial Highlights Fourth quarter net revenue of $3,053 million, up 28.6% compared to $2,375 million in the fourth quarter of 2023.Fourth quarter net income of $15.4 million, compared to net loss of $7.2 million in the fourth quarter of 2023.Fourth quarter Adjusted EBITDA¹ of $167 million, up 17.4% versus $143 million in the fourth quarter of 2023.Full year net revenue of $11,266 million, up 27.6% compared to $8,826 million in 2023.Full year net loss of $20.5 million, compared to net loss of $156.8 million in 2023.Full year Adjusted EBITDA¹ of $588 million, up 9.3% versus $538 million in 2023. When excluding a certain $30 million Quality Incentive Payment (QIP) in 2023, Adjusted EBITDA was up 15.9% compared to $508 million in 2023. This certain vendor QIP program has reached its conclusion, as previously disclosed. On January 20, 2025, announced BrightSpring entered into a definitive agreement to divest the Community Living business to Sevita for $835 million, subject to customary closing adjustments.Increased 2025 Revenue and Adjusted EBITDA Guidance, excluding Community Living: Revenue: $11,600 – $12,100 millionAdjusted EBITDA¹: $545 – $560 million “In 2024, BrightSpring’s focus on quality and third-party satisfaction scores, growth in customers and patients served, and efficiency and best practices across the organization resulted in another excellent year of both operational and financial performance,” said Jon Rousseau, Chairman, President and Chief Executive Officer of the Company. “I am proud of our team’s commitment and capabilities that underpin these results, as well as the organization’s impact throughout communities. We are enthusiastic about what’s in front of us in 2025, as we further drive our mission to reach people who need the Company’s beneficial service solutions. We expect the recently announced divestiture of Community Living to result in a more streamlined organization with greater capital flexibility and increased growth rates.” Fourth Quarter 2024 Financial Results Net revenue of $3,053 million, up 28.6% compared to $2,375 million in the fourth quarter of 2023. Gross profit of $422 million, up 14.4% compared to $369 million in the fourth quarter of 2023. Net income of $15.4 million, compared to net loss of $7.2 million in the fourth quarter of 2023. Adjusted EBITDA¹ of $167 million, up 17.4% compared to $143 million in the fourth quarter of 2023. Full Year 2024 Financial Results Net revenue of $11,266 million, up 27.6% compared to $8,826 million in 2023. Gross profit of $1,588 million, up 10.8% compared to $1,434 million in 2023. Excluding a certain $30 million receipt of QIP in 2023, gross profit growth rate was 13.2%. Net loss of $20.5 million, compared to net loss of $156.8 million in 2023. Adjusted EBITDA¹ of $588 million, up 9.3% compared to $538 million in 2023 When excluding a certain $30 million QIP in 2023, Adjusted EBITDA¹ was up 15.9% compared to $508 million in 2023. ¹Adjusted EBITDA is a non-GAAP financial measure. Please see “Non-GAAP Financial Information” and the end of this press release for a reconciliation of Adjusted EBITDA to net loss, the most directly comparable financial measure prepared in accordance with GAAP. Key Financials   Three Months Ended   Year Ended    December 31,   December 31,     2024   2023  %  2024   2023  %($ in millions)            Pharmacy Solutions Revenue $2,397  $1,785  34% $8,754  $6,522  34%Provider Services Revenue  656   589  11%  2,512   2,304  9%Total Revenue $3,053  $2,375  29% $11,266  $8,826  28%   Three Months Ended   Year Ended    December 31,   December 31,     2024   2023  %  2024   2023  %($ in millions)            Pharmacy Solutions segment EBITDA $113  $93  22% $395  $371  6%Provider Services segment EBITDA  99   86  16%  361   307  18%Total Segment Adjusted EBITDA $212  $178  19% $755  $678  11%Corporate Costs  (45)  (36) -   (167)  (140) - Total Company Adjusted EBITDA $167  $143  17% $588  $538  9% Full Year 2025 Financial Guidance For the full year 2025, BrightSpring is increasing guidance, which excludes the Community Living business and the effects of any future closed acquisitions. All growth rates reflect growth from the full year 2024 revenue and Adjusted EBTIDA results, excluding the Community Living business. Net Revenue of $11,600 million to $12,100 million, or 15.2% to 20.1% growth over full year 2024. Pharmacy Segment Revenue of $10,150 million to $10,600 million, or 15.9% to 21.1% growth over full year 2024.Provider Segment Revenue of $1,450 million to $1,500 million, or 10.0% to 13.8% growth over full year 2024. Adjusted EBITDA² of $545 million to $560 million, or 18.4% to 21.7% growth over full year 2024. A copy of the Company’s fourth quarter and fiscal year 2024 earnings presentation is available on the Company’s investor relations website, https://ir.brightspringhealth.com/ ²A reconciliation of the foregoing guidance for the non-GAAP metric of Adjusted EBITDA to GAAP net loss cannot be provided without unreasonable effort because of the inherent difficulty of accurately forecasting the occurrence and financial impact of the various adjusting items necessary for such reconciliation that have not yet occurred, are out of our control, or cannot be reasonably predicted. For the same reasons, the Company is unable to assess the probable significance of the unavailable information, which could have a material impact on its future GAAP financial results. Webcast and Conference Call Details BrightSpring will host a conference call today, March 6, 2025, at 8:30 a.m. Eastern Time. Investors interested in listening to the conference call are required to register online. A live and archived webcast of the event will be available on the “Events & Presentations” section of the BrightSpring website at https://ir.brightspringhealth.com/. The Company has posted supplemental financial information on the fourth quarter and fiscal year 2024 results that it will reference during the conference call. The supplemental information can be found under the “Events & Presentations” on the Company’s investor relations page. About BrightSpring Health Services BrightSpring Health Services provides complementary home- and community-based pharmacy and provider health solutions for complex populations in need of specialized and/or chronic care. Through the Company’s service lines, including pharmacy, home health care and primary care, and rehabilitation and behavioral health, we provide comprehensive and more integrated care and clinical solutions in all 50 states to over 450,000 customers, clients and patients daily. BrightSpring has consistently demonstrated strong and often industry-leading quality metrics across its services lines while improving the quality of life and health for high-need individuals and reducing overall costs to the healthcare system. Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect our current views with respect to, among other things, our operations and financial performance. Forward-looking statements include all statements that are not historical facts. These forward-looking statements may relate to matters which include, but are not limited to, industries, business strategy, goals and expectations concerning our market position, future operations, margins, profitability, capital expenditures, liquidity and capital resources and other financial and operating information. In some cases, we have used words such as “anticipate,” “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “future,” “will,” “seek,” “foreseeable,” “target,” “guidance,” the negative version of these words, or similar terms and phrases to identify these forward-looking statements. The forward-looking statements are based on management’s current expectations and are not historical facts or guarantees of future performance. The forward-looking statements relate to the future and are therefore subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify. Our expectations, beliefs, and projections are expressed in good faith and we believe there is a reasonable basis for them. However, there can be no assurance that management’s expectations, beliefs, and projections will result or be achieved. Actual results may differ materially from these expectations due to changes in global, regional, or local economic, business, competitive, market, regulatory, and other factors, many of which are beyond our control. We believe that these factors include but are not limited to the following: our operation in a highly competitive industry;our inability to maintain relationships with existing patient referral sources or establish new referral sources;changes to Medicare and Medicaid rates or methods governing Medicare and Medicaid payments for our services;cost containment initiatives of third-party payors, including post-payment audits;the implementation of alternative payment models and the transition of Medicaid and Medicare beneficiaries to managed care organizations may limit our market share and could adversely affect our revenues;changes in the case mix of patients, as well as payor mix and payment methodologies, and decisions and operations of third-party organizations;our reliance on federal and state spending, budget decisions, and continuous governmental operations which may fluctuate under different political conditions;changes in drug utilization and/or pricing, PBM contracts, and Medicare Part D/Medicaid reimbursement, which may negatively impact our profitability;changes in our relationships with pharmaceutical suppliers, including changes in drug availability or pricing;reliance on the continual recruitment and retention of nurses, pharmacists, therapists, caregivers, direct support professionals, and other qualified personnel, including senior management;compliance with or changes to federal, state, and local laws and regulations that govern our employment practices, including minimum wage, living wage, and paid time-off requirements;fluctuation of our results of operations on a quarterly basis;harm caused by labor relation matters;limitations in our ability to control reimbursement rates received for our services if we are unable to maintain or reduce our costs to provide such services;delays in collection or non-collection of our accounts receivable, particularly during the business integration process;failure to manage our growth effectively, which may inhibit our ability to execute our business plan, maintain high levels of service and satisfaction or adequately address competitive challenges;our ability to identify, successfully complete and manage acquisitions, joint ventures, and other strategic initiatives, including the pending sale of our Community Living business;our ability to continue to provide consistently high quality of care;maintenance of our corporate reputation or the emergence of adverse publicity, including negative information on social media or changes in public perception of our services;contract continuance, expansion and renewal with our existing customers, including renewals at lower fee levels, customers declining to purchase additional services from us, or reduction in the services received from us pursuant to those contracts;effective investment in, implementation of improvements to and proper maintenance of the uninterrupted operation and data integrity of our information technology and other business systems;security breaches, loss of data, and other disruptions, which could compromise sensitive business or patient information; cause a loss of confidential patient data, employee data or personal information; or prevent access to critical information and thereby expose us to liability, litigation, and federal and state governmental inquiries and damage our reputation and brand;risks related to credit card payments and other payment methods;potential substantial malpractice or other similar claims;various risks related to governmental inquiries, regulatory actions, and whistleblower and other lawsuits, which may not be entirely covered by insurance;our current insurance program, which may expose us to unexpected costs, particularly if we incur losses not covered by our insurance or if claims or losses differ from our estimates;factors outside of our control, including those listed, which have required and could in the future require us to record an asset impairment of goodwill;a pandemic, epidemic, or outbreak of an infectious disease;inclement weather, natural disasters, acts of terrorism, riots, civil insurrection or social unrest, looting, protests, strikes, or street demonstrations; andour inability to adequately protect our intellectual property rights. The forward-looking statements included in this press release are made only as of the date of this press release, and we undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as required by law. These factors should not be construed as exhaustive, and should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, our actual results may vary in material respects from those projected in these forward-looking statements. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Our forward- looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures, investments, or other strategic transactions we may make. For additional information on these and other factors that could cause BrightSpring’s actual results to differ materially from expected results, please see our filings with the Securities and Exchange Commission (the “SEC”), which are accessible on the SEC’s website at www.sec.gov. Non-GAAP Financial Measures This press release contains “non-GAAP financial measures,” including “EBITDA” and “Adjusted EBITDA,” which are financial measures that either exclude or include amounts that are not excluded or included in the most directly comparable measures calculated and presented in accordance with accounting principles generally accepted in the United States, or GAAP. EBITDA and Adjusted EBITDA have been presented in this release as supplemental measures of financial performance that are not required by, or presented in accordance with, GAAP, because we believe they assist investors and analysts in comparing our operating performance across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our core operating performance. Management also believes that these measures are useful to investors in highlighting trends in our operating performance, while other measures can differ significantly depending on long-term strategic decisions regarding capital structure, the tax jurisdictions in which we operate and capital investments. Management uses EBITDA and Adjusted EBITDA to supplement GAAP measures of performance in the evaluation of the effectiveness of our business strategies, to make budgeting decisions, to establish and award discretionary annual incentive compensation, and to compare our performance against that of other peer companies using similar measures. Management supplements GAAP results with non-GAAP financial measures to provide a more complete understanding of the factors and trends affecting the business than GAAP results alone. EBITDA and Adjusted EBITDA are not GAAP measures of our financial performance and should not be considered as an alternative to net loss as a measure of financial performance or any other performance measures derived in accordance with GAAP. Additionally, these measures are not intended to be a measure of free cash flow available for management’s discretionary use as they do not consider certain cash requirements such as tax payments, debt service requirements, total capital expenditures, and certain other cash costs that may recur in the future. Management defines EBITDA as net loss before income tax expense (benefit), interest expense, and depreciation and amortization. Management also defines Adjusted EBITDA as EBITDA, further adjusted to exclude non-cash share-based compensation, acquisition, integration and transaction-related costs, restructuring and divestiture-related and other costs, goodwill impairment, legal costs and settlements associated with certain historical matters for PharMerica, significant projects, management fees, and unreimbursed COVID-19 related costs. The presentations of these measures have limitations as analytical tools and should not be considered in isolation, or as a substitute for analysis of our results as reported under GAAP. Because not all companies use identical calculations, the presentations of these measures may not be comparable to other similarly titled measures of other companies and can differ significantly from company to company. Please see the end of this press release for reconciliations of non-GAAP financial measures to the most directly comparable financial measure prepared in accordance with GAAP. BrightSpring Contact: Investor Relations:David Deuchler, CFAGilmartin Group LLCir@brightspringhealth.com Media Contact:Leigh Whiteleigh.white@brightspringhealth.com502.630.7412  BrightSpring Health Services, Inc. and SubsidiariesConsolidated Balance SheetsDecember 31, 2024 and 2023(In thousands, except share and per share data)(Unaudited)   December 31, 2024  December 31, 2023 Assets      Current assets:      Cash and cash equivalents $61,253  $13,071 Accounts receivable, net of allowance for credit losses  1,028,654   881,627 Inventories  640,568   402,776 Prepaid expenses and other current assets  162,579   159,167 Total current assets  1,893,054   1,456,641 Property and equipment, net of accumulated depreciation of $450,309 and $368,089 at December 31, 2024 and 2023, respectively  250,286   245,908 Goodwill  2,671,524   2,608,412 Intangible assets, net of accumulated amortization  811,482   881,476 Operating lease right-of-use assets, net  249,748   267,446 Deferred income taxes, net  5,575   — Other assets  44,471   72,838 Total assets $5,926,140  $5,532,721 Liabilities, Redeemable Noncontrolling Interests, and Equity      Current liabilities:      Trade accounts payable $941,292  $641,607 Accrued expenses  356,538   492,363 Current portion of obligations under operating leases  69,665   71,053 Current portion of obligations under financing leases  12,113   11,141 Current portion of long-term debt  48,725   32,273 Total current liabilities  1,428,333   1,248,437 Obligations under operating leases, net of current portion  187,614   201,655 Obligations under financing leases, net of current portion  24,991   22,528 Long-term debt, net of current portion  2,561,858   3,331,941 Deferred income taxes, net  —   23,668 Long-term liabilities  71,759   91,943 Total liabilities  4,274,555   4,920,172 Redeemable noncontrolling interests  3,730   27,139 Shareholders’ equity:      Common stock, $0.01 par value, 1,500,000,000 and 137,398,625 shares authorized, 174,245,990 and 117,857,055 shares issued and outstanding at December 31, 2024 and 2023, respectively $1,742  $1,179 Preferred stock, $0.01 par value, 250,000,000 authorized; no shares issued and outstanding at December 31, 2024; no shares authorized, issued or outstanding at December 31, 2023  —   — Additional paid-in capital  1,866,850   771,336 Accumulated deficit  (222,155)  (200,319)Accumulated other comprehensive income  1,418   12,544 Total shareholders’ equity  1,647,855   584,740 Noncontrolling interest  —   670 Total equity  1,647,855   585,410     Total liabilities, redeemable noncontrolling interests, and equity $5,926,140  $5,532,721  BrightSpring Health Services, Inc. and SubsidiariesConsolidated Statements of OperationsFor the three and twelve months ended December 31, 2024 and 2023(In thousands, except per share amounts)(Unaudited)   For the Three Months Ended  For the Years Ended   December 31,  December 31,   2024  2023  2024  2023 Revenues:            Products $2,397,059  $1,785,457  $8,754,282  $6,522,450 Services  655,742   589,087   2,512,190   2,303,725 Total revenues  3,052,801   2,374,544   11,266,472   8,826,175 Cost of goods  2,192,520   1,614,641   8,008,501   5,840,716 Cost of services  438,382   391,188   1,669,536   1,551,665 Gross profit  421,899   368,715   1,588,435   1,433,794 Selling, general, and administrative expenses  342,846   300,453   1,382,061   1,286,614 Operating income  79,053   68,262   206,374   147,180 Loss on extinguishment of debt  —   —   12,726   — Interest expense, net  54,866   83,054   228,386   324,593 Income (loss) before income taxes  24,187   (14,792)  (34,738)  (177,413)Income tax expense (benefit)  8,783   (7,591)  (14,217)  (20,578)Net income (loss)  15,404   (7,201)  (20,521)  (156,835)Net loss attributable to noncontrolling interests  (595)  (664)  (2,459)  (2,232)Net income (loss) attributable to BrightSpring Health Services, Inc. and subsidiaries $15,999  $(6,537) $(18,062) $(154,603)             Net income (loss) per common share:            Income (loss) per share – basic $0.08  $(0.06) $(0.09) $(1.31)Income (loss) per share – diluted $0.08  $(0.06) $(0.09) $(1.31)Weighted average shares outstanding:            Basic  200,312   117,857   192,997   117,868 Diluted  213,160   117,857   192,997   117,868  BrightSpring Health Services, Inc. and SubsidiariesConsolidated Statements of Cash FlowsFor the three and twelve months ended December 31, 2024 and 2023(In thousands)(Unaudited)   For the Three Months Ended  For the Years Ended   December 31,  December 31,   2024  2023  2024  2023 Operating activities:            Net income (loss) $15,404  $(7,201) $(20,521) $(156,835)Adjustments to reconcile net income (loss) to cash provided by operating activities:            Depreciation and amortization  54,881   51,012   204,482   202,336 Impairment of long-lived assets  5,454   2,336   10,235   10,631 Change in fair value of contingent consideration, net  2,261   —   2,261   — Payment of contingent consideration in excess of acquisition date fair value  (2,351)  —   (2,351)  — Provision for credit losses  12,102   4,310   33,998   23,237 Amortization of deferred debt issuance costs  2,631   5,225   12,108   20,916 Share-based compensation  13,980   1,817   69,174   3,917 Deferred income taxes, net  1,867   (16,067)  (25,914)  (52,632)Loss on extinguishment of debt  —   —   12,726   — Loss (gain) on disposition of fixed assets  156   (608)  101   349 Other  (1,492)  (362)  (2,451)  (572)Change in operating assets and liabilities, net of acquisitions and dispositions:            Accounts receivable  (15,044)  (10,324)  (179,040)  (127,246)Prepaid expenses and other current assets  10,065   (34,737)  7,595   (34,899)Inventories  (162,249)  (24,584)  (236,514)  28,660 Trade accounts payable  147,646   163,962   303,209   105,649 Accrued expenses  5,452   34,280   (144,580)  193,633 Other assets and liabilities  (151)  (6,659)  (20,744)  (6,361)Net cash provided by operating activities $90,612  $162,400  $23,774  $210,783 Investing activities:            Purchases of property and equipment $(15,311) $(16,834) $(80,913) $(73,527)Acquisitions of businesses, net of cash acquired  (42)  (550)  (59,797)  (63,058)Other  (427)  362   473   2,152 Net cash used in investing activities $(15,780) $(17,022) $(140,237) $(134,433)Financing activities:            Long-term debt borrowings $—  $—  $2,566,000  $— Long-term debt repayments  (11,701)  (7,584)  (3,396,334)  (30,441)Proceeds from issuance of common stock on initial public offering, net  —   —   656,485   — Proceeds from issuance of tangible equity units, net  —   —   389,000   — (Repayments) borrowings of the Revolving Credit Facility, net  (33,800)  (122,350)  12,600   (24,100)Payment of debt issuance costs  (3,857)  —   (47,045)  — Repurchase of shares of common stock  —   (325)  (650)  (650)Proceeds from shares issued under share-based compensation plan  377   —   1,535   598 Taxes paid related to net share settlement of equity awards  (569)  —   (1,196)  — Repurchase of stock options  —   (10,000)  —   (10,000)Payment of contingent consideration  2,351   (1,453)  (1,805)  (1,453)Distributions to redeemable noncontrolling interests  —   —   —   — Purchase of redeemable noncontrolling interest  —   —   (2,316)  — Investment in noncontrolling interests  —   735   —   735 Payment of financing lease obligations  (2,353)  (2,971)  (11,629)  (11,596)Net cash (used in) provided by financing activities $(49,552) $(143,948) $164,645  $(76,907)Net increase (decrease) in cash and cash equivalents  25,280   1,430   48,182   (557)Cash and cash equivalents at beginning of year  35,973   11,641   13,071   13,628 Cash and cash equivalents at end of year $61,253  $13,071  $61,253  $13,071  BrightSpring Health Services, Inc. and SubsidiariesReconciliation of EBITDA and Adjusted EBITDAFor the three and twelve months ended December 31, 2024 and 2023(Unaudited) The following table reconciles net income (loss) to EBITDA and Adjusted EBITDA: ($ in thousands) For the Three Months Ended  For the Years Ended   December 31,  December 31,   2024  2023  2024  2023 Net income (loss) $15,404  $(7,201) $(20,521) $(156,835)Income tax benefit  8,783   (7,591)  (14,217)  (20,578)Interest expense, net  54,866   83,054   228,386   324,593 Depreciation and amortization  54,881   51,012   204,482   202,336 EBITDA $133,934  $119,274  $398,130  $349,516 Non-cash share-based compensation (1)  13,980   1,817   69,174   3,917 Acquisition, integration, and transaction-related costs (2)  9,538   6,980   34,869   20,734 Restructuring and divestiture-related and other costs (3)  9,966   5,676   38,031   21,848 Legal costs and settlements (4)  —   5,989   21,886   127,695 Significant projects (5)  —   1,480   2,604   8,379 Management fees (6)  —   1,383   23,381   5,631 Unreimbursed COVID-19 related costs  —   —   —   88 Total adjustments $33,484  $23,325  $189,945  $188,292 Adjusted EBITDA $167,418  $142,599  $588,075  $537,808  (1)Represents non-cash share-based compensation to certain members of our management and other full-time employees. The year ended December 31, 2024 includes $49.2 million of costs related to new equity awards granted upon the completion of our IPO under the 2024 Equity Incentive Plan and $15.0 million of previously unrecognized share-based compensation expense related to performance-vesting options under the 2017 Stock Plan, a portion of which vested upon completion of the IPO.(2)Represents transaction costs incurred in connection with planned, completed, or terminated acquisitions, which include investment banking fees, legal diligence and related documentation costs, finance and accounting diligence and documentation; costs associated with the integration of acquisitions, including any facility consolidation, integration travel, or severance; and costs associated with other planned, completed, or terminated non-routine transactions. The year ended December 31, 2024 includes acquisition and integration related costs of $17.4 million, earn-out adjustments from previous acquisitions of $2.4 million, and other non-routine transaction costs of $8.7 million, as compared to acquisition and integration related costs of $3.7 million for the year ended December 31, 2023. These costs also included $6.4 million and $4.7 million of costs related to the IPO Offerings which were not capitalizable for the years ended December 31, 2024 and 2023, respectively.(3)Represents costs associated with restructuring-related activities, including closure costs, and related license impairment, and severance expenses associated with certain enterprise-wide or significant business line cost-savings measures. These costs included $12.7 million of unamortized debt issuance costs associated with the extinguishment of our Second Lien Facility in the year ended December 31, 2024. These costs also included $7.3 million and $10.6 million of intangible asset and other non-cash investment impairment for the years ended December 31, 2024 and 2023, respectively.(4)Represents settlement and defense costs associated with certain historical PharMerica litigation matters, including the Silver matter, all of which were finalized in 2024. See Note 14 “Commitments and Contingencies” within the audited consolidated financial statements and related notes, included elsewhere in this Annual Report on Form 10-K, for additional information.(5)Represents costs associated with certain transformational projects and for the periods presented primarily included general ledger system implementation, pharmacy billing system implementation, and ransomware attack response costs, all of which were finalized in 2024. General ledger system migration and related business intelligence system implementation costs, which were capitalized as development costs and are subsequently amortized in accordance with ASC 350-40, Internal Use Software, were $0.7 million and $2.0 million for the years ended December 31, 2024, and 2023, respectively. Pharmacy billing system implementation costs were $0.7 million and $2.2 million for the year ended December 31, 2024 and 2023, respectively. Ransomware attack response costs were $1.0 million and $3.4 million for the years ended December 31, 2024 and 2023.(6)Represents annual management fees payable to the Managers under the Monitoring Agreement through the date of the IPO, and $22.7 million of termination fees resulting from the Monitoring Agreement being terminated upon completion of the IPO Offerings. All management fees have ceased following the completion of the IPO. BrightSpring Health Services, Inc. and SubsidiariesReconciliation of Adjusted EPSFor the three and twelve months ended December 31, 2024 and 2023(Unaudited) The following table reconciles diluted EPS to Adjusted EPS: (shares in thousands) For the Three Months Ended December 31,  For the Years Ended December 31,   2024  2023  2024  2023 Diluted EPS $0.08  $(0.06) $(0.09) $(1.31)Non-cash share-based compensation (1)  0.07   0.01   0.34   0.03 Acquisition, integration, and transaction-related costs (1)  0.04   0.06   0.17   0.16 Restructuring and divestiture-related and other costs (1)  0.05   0.05   0.19   0.17 Legal costs and settlements (1)  —   0.05   0.11   1.01 Significant projects (1)  —   0.01   0.01   0.07 Management fee (1)  —   0.01   0.12   0.04 Unreimbursed COVID-19 related costs (1)  —   —   —  0.00 Income tax impact on adjustments (2)(3)  (0.02)  (0.05)  (0.29)  (0.10)Adjusted EPS $0.22  $0.08  $0.56  $0.07              Weighted average common shares outstanding used in calculating diluted U.S. GAAP net earnings (loss) per share  213,160   117,857   192,997   117,868 Weighted average common shares outstanding used in calculating diluted Non-GAAP earnings per share  213,160   126,091   202,106   126,355  (1)This adjustment reflects the per share impact of the adjustment reflected within the definition of Adjusted EBITDA.(2)The income tax impact of non-GAAP adjustments is calculated using the estimated tax rate for the respective non-GAAP adjustment.(3)For the year ended December 31, 2024, the income tax impact on adjustments is inclusive of a discrete tax benefit related to the Silver matter that was finalized in connection with the signing of the settlement agreement during the second fiscal quarter of 2024.

Related News